• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 6, 2011

View Archived Issues

Optimer Pharmaceuticals Buoyed by Unanimous Vote

WASHINGTON – Optimism, and eight years of hard work, paid off for Optimer Pharmaceuticals Inc. Tuesday when an FDA advisory committee unanimously recommended approval of Dificid (fidaxomicin) as a treatment for Clostridium difficile infection (CDI). Read More

Merck Expands Ophthalmology Line, Buys Inspire for $430M

Merck & Co. Inc. is acquiring stressed specialty pharma Inspire Pharmaceuticals Inc. for about $430 million. Read More

At AACR Meeting, Optimism That Progress Will Continue

It might be called the cancer patient's theory of relativity: Even when drug development moves at record speed, that speed is still glacial from the perspective of the patient with cancer whose life expectancy may, in the worst cases, be measured in months. Read More

Cephalon Rejects Valeant's Hostile $5.7B Takeover Bid

It took Cephalon Inc. less than a week to decide that Valeant Pharmaceutical International Inc.'s unsolicited offer to buy the biotech was undervalued. Read More

Cubist Resolves Lawsuit with Teva for Cubicin

Cubist Pharmaceuticals Inc. has settled its lawsuit with Teva Pharmaceutical Industries Ltd. and will soon see less money going to litigation and more going to innovation. The lawsuit, filed in 2009 by Cubist, alleged that Jerusalem-based Teva had infringed on Cubist's patent for Cubicin (daptomycin for injection) by filing for FDA approval of a generic version of Cubicin. Read More

Sunesis Finds New Oncology Partner in $60M Millennium Deal

Millennium, of Cambridge Mass., has rescued the kinase inhibitor program in oncology at Sunesis Pharmaceuticals Inc. after development partner Biogen Idec exited the oncology market last fall. Millennium, a unit of Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, inked a licensing agreement that covers the development of Sunesis' oral, Phase I-ready selective pan-Raf kinase inhibitor and an additional preclinical kinase inhibitor program with an undisclosed oncology target. Read More

Stock Movers

Read More

Other News To Note

ProMetic Life Sciences Inc., of Montreal, entered an agreement with Celgene Corp., of Summit, N.J., for the worldwide rights to a commercial application of ProMetic's protein technologies. Under the terms, Abraxis BioScience Inc., a wholly owned subsidiary of Celgene, will forgive a $10 million long-term debt from 2010, effectively terminating the loan agreement four years prior to its original term, in return for intellectual property rights to specific commercial application of the technology within restricted fields of use. Read More

Financings Roundup

Champions Oncology, Inc., of Baltimore, said that it grossed $9.4 million through the private placement of 12.5 million shares of common stock at 75 cents per share. The company said proceeds will be used for sales resources, its Tumorgraft bank and technology platform and to repurchase shares. Read More

Clinic Roundup

Neurocrine Biosciences Inc., of San Diego, completed dosing and preliminary assessment of its initial cohort of patients in an open-label, Phase IIa trial of NBI-98854 for tardive dyskinesia. NBI-98854 is a vesicular monoamine transporter 2 inhibitor (VMAT2). After 12 days of treatment with the drug, test subjects showed improvement in the abnormal hyperkinetic movements caused by tardive dyskinesia. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe